Remaining pipeline and cash cushion investor blow as Targacept ends another programme
This article was originally published in Scrip
After Targacept announced the unsuccessful end of its third clinical development programme this year and said for the second time in 2012 that it would lay off employees, the company - which is focused on therapeutics that selectively target neuronal nicotinic receptors (NNRs) to treat nervous system diseases and disorders - experienced a relatively small 11.1% decline in its stock price on 17 September, given its recent string of failures.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.